EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR
EBR:ARGX (3/7/2025, 7:00:00 PM)
555.4
-22.8 (-3.94%)
The current stock price of ARGX.BR is 555.4 EUR. In the past month the price decreased by -12.12%. In the past year, price increased by 55.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B | ||
1MRNA.MI | MODERNA INC | N/A | 12.34B |
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,148 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1148
Company Website: https://www.argenx.com/
Investor Relations: https://www.argenx.com/investors
Phone: 31763030
The current stock price of ARGX.BR is 555.4 EUR. The price decreased by -3.94% in the last trading session.
The exchange symbol of ARGENX SE is ARGX and it is listed on the Euronext Brussels exchange.
ARGX.BR stock is listed on the Euronext Brussels exchange.
25 analysts have analysed ARGX.BR and the average price target is 658.04 EUR. This implies a price increase of 18.48% is expected in the next year compared to the current price of 555.4. Check the ARGENX SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARGENX SE (ARGX.BR) has a market capitalization of 33.75B EUR. This makes ARGX.BR a Large Cap stock.
ARGENX SE (ARGX.BR) currently has 1148 employees.
ARGENX SE (ARGX.BR) has a support level at 334 and a resistance level at 559.79. Check the full technical report for a detailed analysis of ARGX.BR support and resistance levels.
The Revenue of ARGENX SE (ARGX.BR) is expected to grow by 60.95% in the next year. Check the estimates tab for more information on the ARGX.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARGX.BR does not pay a dividend.
ARGENX SE (ARGX.BR) will report earnings on 2025-05-08, before the market open.
The PE ratio for ARGENX SE (ARGX.BR) is 253.61. This is based on the reported non-GAAP earnings per share of 2.19 and the current share price of 555.4 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.BR.
ChartMill assigns a technical rating of 3 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR is one of the better performing stocks in the market, outperforming 91.68% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ARGX.BR. ARGX.BR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS increased by 146.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 38.03% | ||
ROA | 17.37% | ||
ROE | 19.54% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 78% to ARGX.BR. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 346.1% and a revenue growth 60.95% for ARGX.BR